Opiant Pharmaceuticals (OPNT) Receives a Buy from Northland Securities

By Jason Carr

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Opiant Pharmaceuticals (OPNTResearch Report), with a price target of $42.00. The company’s shares closed last Monday at $15.06.

According to TipRanks.com, Byrnes is ranked 0 out of 5 stars with an average return of -16.6% and a 24.1% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Adamas Pharmaceuticals, Aridis Pharmaceuticals, and Flexion Therapeutics.

Opiant Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $42.00.

See today’s analyst top recommended stocks >>

Based on Opiant Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $1.58 million. In comparison, last year the company had a GAAP net loss of $918K.

Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Opiant Pharmaceuticals, with its team of addiction experts, is headquartered in Santa Monica, California. The Company, formerly known as Lightlake Therapeutics, was founded in 2009 by the late Dr. David Sinclair based on his pioneering research demonstrating that opioid antagonists could be used as a symptom-driven treatment for alcoholism